Published in final edited form as:

Pain. 2013 August ; 154(8): 1442–1448. doi:10.1016/j.pain.2013.05.004.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone

Perrine Roux^{1,2,3,4}, Maria A. Sullivan¹, Julien Cohen^{2,3}, Lionel Fugon^{2,3}, Jermaine D. Jones¹, Suzanne K. Vosburg¹, Ziva D. Cooper¹, Jeanne M. Manubay¹, Shanthi Mogali¹, and Sandra D. Comer¹

¹Division on Substance Abuse, New York State Psychiatric Institute, Department of Psychiatry, and College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA

²INSERM U912 (SESSTIM), Marseille, France

³Université Aix Marseille, IRD, UMR-S912, Marseille, France

⁴ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France

Abstract

Aim—Few studies have examined **abuse of prescription opioids (PO)** among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. The current 7-week inpatient study assessed **oral oxycodone** self-administration by patients with chronic pain who had a history of opioid abuse.

Methods—Participants (N=25) were transitioned from their pre-admission prescribed opioid to Bup/Nx. All of the participants were tested under each of the sublingual Bup/Nx maintenance doses (2/0.5, 8/2 or 16/4 mg) in random order. During each maintenance period, participants could self-administer oxycodone orally (0, 10, 20, 40 or 60 mg, PO) or receive money during laboratory sessions. Drug choice (**percent**) was the primary dependent variable. Subjective ratings of clinical pain and withdrawal symptoms also were measured. Mann-Whitney tests compared % drug choice for each active oxycodone dose to placebo. Logistic regression analyses identified correlates of oxycodone preference, defined as 60% or greater choice of oxycodone compared to money.

Results—Pain was significantly reduced while participants were maintained on Bup/Nx compared to pre-admission ratings. No differences in **percent** drug choice were observed between the active oxycodone doses and placebo under each Bup/Nx maintenance dose. However, factors associated with oxycodone preference were: lower Bup/Nx maintenance dose, more withdrawal symptoms and more pain.

Conclusions—These data suggest that Bup/Nx was effective in reducing pain and supplemental oxycodone use. Importantly, adequate management of pain and withdrawal symptoms by Bup/Nx may reduce oxycodone preference in this population.

Corresponding author: Perrine ROUX, PhD perrine.roux@inserm.fr Phone : 0033(4)96102876 .

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

chronic pain; buprenorphine; reinforcing effect; oxycodone; opioid dependence

Introduction

In the United States (US), the problem of non-medical use of prescription opioids (PO) has emerged as a major public health issue [2]. Other countries, such as Australia, New Zealand [12], and Canada [33], also are concerned about the phenomenon of PO abuse. In the US, oxycodone and hydrocodone are among the most commonly prescribed or regularly used opioid, as well as the most commonly diverted PO analgesics [5, 25]. These data have indicated that PO abuse has steadily increased among heroin and recreational polydrug users since 2000 [5]. An additional concern related to the increased use of PO is opioid overdose, which increased in the US from the mid-1990s to the present time [11, 10] and recently became a leading cause of accidental death in the US [1]. Thus, the risks of PO abuse and overdose make physicians reluctant to prescribe POs in general, and access to adequate pain management in drug users in particular is becoming increasingly difficult [39, 20]. In those patients who are prescribed POs for pain relief, misuse may occur in pain patients with no history of opioid abuse who become dependent on the medications for their reinforcing properties, whether good drug effects or relief of anxiety or mood symptoms, or misuse may occur in drug-seeking individuals with pre-existing opioid abuse histories. Thus, balancing the need for effective pain relief and reducing the risks of opioid abuse and overdose remains a challenge for public health policy [7].

In this context of easy access to opioid analgesics for the general population, opioid overdoses due to diversion [8] and difficulties in accessing treatment for pain and opioid dependence, expanding access to a less risky treatment for pain and opioid dependence is a logical and plausible public health response.

For decades, buprenorphine, a partial mu-opioid agonist, has been used to treat acute and chronic pain [16]. More recently, a sublingual formulation of buprenorphine has been used to treat opioid dependence [38] in both substance abuse treatment clinics and in primary care settings [18]. Although sublingual buprenorphine is not approved by the FDA for treating pain, some have suggested its use in the management of concurrent pain and opioid dependence [23]. However, few studies have systematically examined whether buprenorphine maintenance alters prescription opioid abuse in this population. Thus, assessment of the effectiveness of buprenorphine in treating pain and also reducing the abuse liability of oxycodone would be relevant to the public health problem of PO abuse. In the current study, patients with chronic, non-malignant pain who were abusing their prescription opioid medications were maintained on different doses of sublingual buprenorphine/naloxone (2/0.5, 8/2, and 16/4 mg per day in divided doses) and given the opportunity to self-administer oxycodone in a laboratory setting.

Methods

Participants

All of the participants were currently under the care of a physician for mild to moderate chronic, non-malignant pain. They were also required to meet DSM-IV criteria for opioid dependence, but were not seeking treatment for their opioid dependence. Potential participants were excluded from the study if they had a current major Axis I psychopathology other than opioid dependence (i.e. schizophrenia or bipolar disorder) or met DSM-IV criteria for dependence on drugs other than opioids, nicotine or caffeine or had

a primary diagnosis of neuropathic pain, malignant pain, headache, or chronic lower back pain with failed surgeries. Current buprenorphine maintenance and history of failed treatment with buprenorphine maintenance for pain also were exclusionary.

Data Collection

After completing an initial telephone interview, eligible participants came into the laboratory to provide consent to receive additional screening, which included completing detailed medical history and drug use questionnaires, interviews with a psychologist and psychiatrist, and a medical evaluation conducted by a physician. Prescription opioid use was ascertained in multiple ways (self-report, verification with prescribing physician, and/or presentation of prescription opioid bottles) and was converted to number of morphine equivalents used per day. We also collected sociodemographic data such as age, gender, ethnicity, education and employment. Urine drug toxicologies (using urine quick tests) also were performed several times during screening to test for opioids, benzoylecgonine (cocaine metabolite), benzodiazepines, cannabinoids and amphetamines. During laboratory sessions, subjective responses were measured and reinforcing effects of oxycodone were assessed, as described below.

Study Design

This study was described in detail in a previous paper that presented preliminary results [17]. Individuals who met the eligibility criteria were admitted to an inpatient research unit for 7 weeks and transitioned from their baseline prescription opioid to buprenorphine/naloxone combination (Bup/Nx). During the first week after admission, participants were withdrawn from their previous opioid analgesic regimen and stabilized on one of three doses of Bup/Nx (2/0.5, 8/2, or 16/4 mg/day). The total daily Bup/Nx dose was administered QID in equal divided doses throughout the day (Figure 1). Participants were treated for emergent withdrawal symptoms with various supplemental medications until withdrawal symptoms dissipated based on self-report and observer ratings. Patients were maintained on each Bup/Nx dose for approximately 2 weeks: 1 week of stabilization followed by 1 week of laboratory testing. Each participant received all three Bup/Nx doses in random order under double-blind conditions.

Reinforcing Effects

During each maintenance period, participants could self-administer oral oxycodone (0, 10, 20, 40 or 60 mg) during separate laboratory sessions. Each laboratory day consisted of two types of sessions, a sample session during which participants were provided with one of the possible doses of drug (oxycodone) and US\$20, and a self-administration (choice) session that occurred a few hours later on the same day. During the sample session, the subjective, physiological, and analgesic effects of oxycodone were measured. During the choice session, participants could self-administer the dose of oxycodone that was given during the sample session or receive money. Participants then completed a self-administration task to receive portions of the dose of drug or money they sampled (0–100% in increments of 10%). For each 10% increment of drug or money, participants were required to complete an increasing number of finger presses on a computer mouse (50, 100, 200, 400, 800, 1200, 1600, 2000, 2400, 2800). Immediately following the self-administration task, money and/or the total amount of drug earned during the task was administered. The sample session began at approximately 11 am and the choice session began at approximately 3 pm (Figure 1).

Subjective Effects

All of the questionnaires used in this study were described in our previous article [17]. For the present analysis, opioid withdrawal symptoms and clinical pain were measured after

administration of the first daily Bup/Nx maintenance dose. Subjective symptoms of opioid withdrawal were assessed with the Subjective Opioid Withdrawal Scale (SOWS; range: 0-64 [9]). Clinical pain assessment was made using the 15-item Short-form McGill Pain Questionnaire [26] based on their general pain condition while maintained on Bup/Nx. Clinical pain was also assessed with the MPQ at the first screening visit prior to initiation of Bup/Nx maintenance.

Statistical analyses

For the present analysis, we used only a subset of the dependent variables collected during the study because of our focused interest in the impact of Bup/Nx maintenance dose, pain level, and withdrawal symptoms on oxycodone self-administration. The time point used in our analyses was 1 hour after the first Bup/Nx dose administration in order to capture peak Bup/Nx effects on pain and opioid withdrawal symptoms in the absence of oxycodone effects.

In addition, as we selected only individuals who completed the 7-week inpatient laboratory period, we compared participants who had complete data for the outcomes of interest to those who did not in order to confirm the absence of a selection bias.

The first analysis consisted of assessing the effectiveness of Bup/Nx on pain perception comparing the MPQ score at baseline before Bup/Nx initiation and at each laboratory session under the different Bup/Nx maintenance doses. We performed a bivariate analysis between MPQ score at baseline and MPQ score under each Bup/Nx maintenance dose using a generalized estimating equations (GEE) model to take into account the intra-individual correlation for pain measurements under Bup/Nx maintenance. In addition, we used a linear regression model based on GEE to assess the association between MPQ pain score and Bup/Nx maintenance doses.

Next, we confirmed the results of our previous paper [17] comparing the reinforcing effect of oxycodone among the different dosing conditions (Bup/Nx and oxycodone) using a repeated-measures ANOVA with a significance level of alpha at 0.05. A Mann-Whitney test was performed to compare the difference between percent drug choice for placebo and each active oxycodone dose condition: placebo versus 10, 20, 40 and 60 mg.

To investigate the risk of oxycodone self-administration, we generated a variable called “oxycodone preference,” defined as self-administration of 60% or more of the dose of oxycodone during the choice sessions. Then we used a logit model based on generalized estimating equations (GEE) [40] to identify variables associated with oxycodone preference. This approach was used in order to study factors associated with oxycodone preference during laboratory sessions, while taking into account the correlation between repeated measures on the same individuals [3]. We used an unstructured covariance matrix to model the correlation between the repeated measures. Variables with *p*-values <0.20 in the bivariate analysis were considered eligible for the final model, which was built using a backward procedure based on the log-likelihood ratio-test.

In addition, we assessed the association between the two variables that have pain dimensions, the pain score and the withdrawal score measured respectively with the MPQ and the SOWS, and also their possible interaction with oxycodone self-administration. Then, we performed two separate multivariate models to identify factors associated with “oxycodone preference” using first MPQ score and then SOWS score as explanatory variables.

All of the analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, USA) and Stata version 10.1 (Stata Corp, Texas, USA) for Windows software packages.

Results

During the enrollment phase of the study, 191 individuals were assessed for eligibility and 140 were excluded because they did not meet the inclusion criteria (N=78; medical rule out (N=21), psychiatric rule out (N=10), not opioid abusing/dependent (N=29), other substance dependence (N=13), or other (N=5)) or lost to follow-up (N=62). Of the 51 who were randomized to the trial, 8 discontinued prior to the inpatient phase (medical drop (N=2), not interested in treatment (N=5) and lost to follow-up (N=1)). Among the 43 participants who entered the inpatient study, 12 dropped before the end of the study (2 for medical reasons, 2 for non-compliance, 7 for self-withdrawal and 1 for another reason). Of the 31 participants who completed the 7-week inpatient laboratory period, 6 participants completed a pilot phase during which a different oxycodone dose range was tested, so we only used data from the remaining 25 participants for our analyses. The participants who were selected for the analyses were similar to the others who were excluded regarding all the socio-demographic variables. Data from a total of 25 participants were used in the analyses, accounting for 375 observations. Of the 25 participants selected for the analyses, the median [interquartile range (IQR)] age was 48 (43–54) years and 9 (36%) were women. Nine (36%) of the participants were African American, 8 (32%) were Hispanic and 8 (32%) were Caucasian. Reasons for study discontinuation among the 18 participants who did not complete the 7-week study were: psychiatric issues (2), intolerance to environment (2), intolerance to Bup/Nx (2 for nausea and 1 for heavy sedation), behavioral issues (5), seeking treatment (1) and lost to follow-up (5).

The median [IQR] duration of PO use was 5 [2-8] years. Prescription opioids that were used during screening included mainly oxycodone, hydrocodone, hydromorphone and tramadol. The median [IQR] number of pills used per day was 7 [4-10], corresponding to 60 [38-144] mg of morphine equivalents (Table 1). At the screening visit, 9 (36%) of the participants had urine samples positive for cocaine. Only one participant reported using heroin during the previous month. Among the 21 participants who completed the McGill Pain Questionnaire at baseline, the median [IQR] pain score at the screening visit was 38 [30-50]. The median [IQR] MPQ score under Bup/Nx maintenance for the 25 participants accounting for 375 timepoints was 21 [15-31]. MPQ score significantly decreased between baseline and laboratory sessions (coefficient [95% CI] = -15.88 [-18.67, -13.10], $p < 0.001$), suggesting that Bup/Nx had a positive impact on pain score relative to pre-study pain ratings. Moreover, compared to 2 mg Bup/Nx, 8 mg Bup/Nx significantly decreased MPQ pain score [OR (95% CI) = -1.68 (-3.15 ; -0.21); $P = 0.03$] and even more under the 16 mg Bup/Nx dose condition [OR (95% CI) = -2.74 (-4.21 ; -1.27); $P < 0.001$].

Consistent with our previous paper [17], oxycodone was not self-administered above placebo levels at any dose tested nor did it vary as a function of Bup/Nx maintenance dose condition (Figure 2). Mann-Whitney tests revealed no significant differences ($p > 0.05$) between oxycodone placebo and active oxycodone doses under the 3 Bup/Nx doses (2/0.5, 8/2 and 16/4 mg). Although oxycodone produced minimal reinforcing effects overall, during 41 (11%) of the sessions, participants chose more than 60% of the available dose of oxycodone, accounting for 9 (36%) participants. Withdrawal symptoms were reported in 307 (83%) sessions with a median [IQR] score of 4 [1-9] out of a maximum possible score of 64. The results of the bivariate analysis are presented in Table 1. We excluded from the analyses the variables found in fewer than 10% of the 'participants' such as self-reported heroin use (1 participant), self-reported cannabis use (1 participant), positive cannabis toxicology (2 participants), and positive methadone toxicology (2 participants). The

variables eligible for the final model are indicated in bold type in Table 1. Some baseline variables were found to be associated with oxycodone ‘preference’ such as being Caucasian, reporting use of a higher number of PO pills per day, using more morphine equivalents per day, and having a urine sample positive for benzodiazepines at the baseline interview. Focusing on the laboratory session dependent variables, the results showed that the highest Bup/Nx maintenance dose (16/4 mg) was associated with less oxycodone preference. Furthermore, higher pain scores using the MPQ were associated with greater oxycodone preference. In addition, higher total SOWS scores were associated with oxycodone preference.

The results presented in Table 2 show two different models after multiple adjustments, one including a withdrawal symptoms variable and the other a pain variable. Both tables, Table 2a and Table 2b, show that two variables remained associated with oxycodone preference, Bup/Nx dose and withdrawal/pain variable. When participants were maintained on the highest dose of Bup/Nx (16/4 mg), they had a two-fold lower risk of preferring oxycodone. Furthermore, those who reported more withdrawal symptoms [OR (95%CI) = 1.96 [1.29-3.00]; P=0.002] and those who had higher pain scores [OR (95%CI)=1.59 [1.15-2.20]; P=0.005] were more likely to self-administer oxycodone. Interestingly, the number of morphine equivalents used per day at baseline did not remain significantly associated with the outcome. No significant interaction was found between MPQ pain score and SOWS score regarding oxycodone preference (P=0.44). However, we found a significant association between MPQ pain score and SOWS score [OR (95%CI)=0.85 (0.63-1.07); P<0.001].

Discussion

Overall, the data indicate that Bup/Nx-maintained opioid-dependent patients with pain do not robustly self-administer oxycodone, as described in our previous article [17]. This result is consistent with the conclusions drawn in a major article on buprenorphine pharmacology showing that the effects of morphine, a full mu-receptor selective opioid agonist similar to oxycodone [30], were significantly attenuated when given to participants during the time of chronic buprenorphine administration [14].

In addition, Bup/Nx maintenance showed a positive impact on pain in our participants, with greater analgesic effects under maintenance on higher doses of Bup/Nx, especially with 16/4 mg. These findings are of great interest because they demonstrate the potential utility of Bup/Nx for treating pain in populations who also abuse prescription opioids. Indeed, buprenorphine is known as an effective opioid maintenance treatment for opioid dependence and studies have previously shown that buprenorphine is effective in relieving pain in non-dependent and opioid-dependent individuals under certain conditions. For example, a recent randomized study in adults with acute pain showed that sublingual buprenorphine is as effective at reducing pain as intravenous morphine [13]. In a sample of opioid-naïve patients with chronic back pain, another randomized trial demonstrated the efficacy of transdermal buprenorphine in reducing pain [34]. Another article reviewed the treatment options for opioid dependence and pain and mentioned the possibility of using the partial mu-agonist buprenorphine in the management of concurrent pain and opioid addiction [23]. In addition, a recent randomized study showed that in patients with chronic pain, there is a similar analgesic and tolerability profile when patients are converted from hydrocodone/acetaminophen (Vicodin®) to transdermal buprenorphine [31]. Finally, a retrospective study reported positive results in pain reduction with Bup/Nx to treat co-occurring chronic non-cancer pain and opioid dependence in a primary care setting [28]. Data from our study suggest that among patients with co-occurring pain and opioid abuse, higher doses of

buprenorphine are more effective than lower doses for simultaneously controlling both pain and opioid abuse.

To present our findings in a more “public health” approach, we performed further analyses regarding oxycodone preference

Although our findings suggest that buprenorphine may be effective in reducing the reinforcing effects of oxycodone among patients with chronic pain who abuse their prescription opioids, an in-depth analysis of the correlates of preference for oxycodone under buprenorphine/naloxone maintenance seemed to be important to identify some potential factors associated with the abuse liability of oxycodone in this population. After adjusting the model aimed at identifying factors associated with oxycodone preference, no variable related to participant baseline characteristics remained associated with oxycodone preference. It is interesting to note that participants who reported using a higher number of morphine equivalents before entering the study were not more likely to self-administer oxycodone. This result suggests that Bup/Nx is effective in reducing the abuse liability of oxycodone regardless of level of PO use. However, caution is required because our participants were selected according to specific inclusion criteria that could have selected less heavy PO users.

It is known that specific sub-populations might be at risk of abusing prescription opioids such as oxycodone [29]. Our bivariate analysis showed that benzodiazepine users, cannabis users, and those who endorsed using heroin at baseline were more likely to self-administer oxycodone. These findings highlight the importance of identifying patients at higher risk of opioid misuse or addiction as recommended by the Canadian guideline for safe and effective use of opioids for chronic pain [19], as well as circumstances under which opioid misuse is more likely. Interestingly, the variables that remained associated with the oxycodone self-administration were pain score, withdrawal symptoms, and Bup/Nx dose. The results suggested that pain assessment remains a key component to adapt the pharmacological treatment. In this study, higher pain scores and higher withdrawal symptoms scores were associated with more oxycodone self-administration. It has been shown previously that non-medical use of PO was associated with bodily pain in a population of injecting drug users [21]. Moreover, withdrawal symptoms have been found to be a predictor of non-medical use of opioids during opioid maintenance treatment [32]. Our results highlight the difficulty in differentiating pain from withdrawal and from a chronic pain condition. For this reason, several studies have noted the importance of including opioid withdrawal assessments in the management of pain, especially in an opioid-dependent population [35, 37].

In addition, our findings showed that buprenorphine maintenance dose could play a role in oxycodone preference. It is known that suboptimal doses of buprenorphine may have negative consequences on treatment efficacy [24]. Because dose adjustment depends on multiple pharmacokinetic and pharmacodynamic parameters, characterized by inter-individual differences, it is crucial to measure patient perceptions regarding the effectiveness of buprenorphine in alleviating withdrawal symptoms and pain. One strategy for treating chronic pain is to administer opioid doses in an escalating manner. Naliboff and colleagues used this method and showed some improvements in self-reported acute relief from pain without an increase in supplemental opioid use compared to a stable dose strategy [27]. Previous studies have shown that the analgesic effects of buprenorphine could be improved by increasing the dose or by prescribing daily divided doses [22] and that doses of 32 mg or higher could be safe and effective [15]. Indeed, the therapeutic choice of using a partial mu-agonist medication is known to reduce the risk of overdoses compared to other full agonist analgesics [4]. A previous study showed that buprenorphine causes limited respiratory depression with a ceiling effect at higher dose [6].

Although use of a within-subjects, repeated-measures design in participants housed on an inpatient research unit is strong experimentally, some limitations also must be acknowledged. First, the participants we enrolled had to fulfill several inclusion and exclusion criteria, which may have reduced the external validity of the results. Indeed, our sample excluded the most severely opioid dependent individuals and those with certain types of pain (e.g., those with neuropathic pain, multiple failed back surgeries, as well as those with a previous lack of analgesic response to buprenorphine). Thus, further studies are needed in opioid dependent individuals with other types of pain and a more complex addictive profile. Moreover, the highest dose we tested (16 mg) may be considered as inadequate for some patients and may need to be increased to manage both pain and opioid dependence. Also, because oxycodone is commonly abused by the intranasal or intravenous routes, future studies should test higher doses of Bup/Nx in combination with opioid agonists administered by non-oral routes. Finally, the context of laboratory sessions is different from the ecological context of the participants' lives. Therefore, a clinical trial conducted on an outpatient basis and/or an epidemiological study would be appropriate to confirm the present results [36].

Nevertheless, our data suggest that buprenorphine could be an effective medication for those patients who need to be treated for chronic pain and opioid abuse/dependence. Further studies should be implemented to determine the profile of pain patients most likely to abuse prescription opioids.

Acknowledgments

We gratefully acknowledge the support of the National Institute on Drug Abuse in the form of research grants to Maria A. Sullivan (R01 DA20448), Sandra D. Comer (R01 DA16759), and Herbert D. Kleber (P50 DA09236). In addition, we thank Robert Vorel M.D., Ben Bryan M.D., Elias Dakwar M.D., David Mysels M.D., Janet Murray R.N. and Claudia Tindall R.N. for their medical assistance, as well as Elisa Payne B.A., Debra Wolkenfeld B.A., Phillip Saccone B.A., and Joseph Lazar B.A. for their technical assistance.

The authors declare that over the past three years SDC, MAS, SKV, ZDC, JMM, SM and JDJ have received compensation (in the form of partial salary support) from investigator-initiated studies supported by Reckitt-Benckiser Pharmaceuticals, Schering-Plough Corporation, Johnson & Johnson Pharmaceutical Research & Development, Endo Pharmaceuticals, and MediciNova. In addition, SDC has served as a consultant to the following companies: Analgesic Solutions, BioDelivery Sciences, Cephalon, Grunenthal, Inflexxion, King, Neuromed, Pfizer, Salix, and Shire. PR, JC, and LF have no conflicts to report.

References

- [1]. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. *MMWR Morb Mortal Wkly Rep.* 2012; 61(1):10–13. [PubMed: 22237030]
- [2]. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. *Drug Alcohol Depend.* 2008; 94(1-3):38–47. [PubMed: 18063321]
- [3]. Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. *Stat Med.* 1999; 18(19):2655–2679. [PubMed: 10495463]
- [4]. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. *Clin Infect Dis.* 2006; 43(Suppl 4):S197–215. [PubMed: 17109307]
- [5]. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002–2004. *J Pain.* 2005; 6(10):662–672. [PubMed: 16202959]
- [6]. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. *Palliative medicine.* 2006; 20(Suppl 1):s3–8. [PubMed: 16764215]
- [7]. Gilson AM. The concept of addiction in law and regulatory policy related to pain management: a critical review. *Clin J Pain.* 2010; 26(1):70–77. [PubMed: 20026957]

- [8]. Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. *Pain Med.* 2009; 10(Suppl 2):S89–100. [PubMed: 19691688]
- [9]. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). *Addict Behav.* 1990; 15(5):487–490. [PubMed: 2248123]
- [10]. Green TC, Grau LE, Carver HW, Kinzly M, Heimer R. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997–2007. *Drug Alcohol Depend.* 2011; 115(3):221–228. [PubMed: 21131140]
- [11]. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. *JAMA.* 2008; 300(22):2613–2620. [PubMed: 19066381]
- [12]. Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. *Anaesth Intensive Care.* 2011; 39(5):804–823. [PubMed: 21970125]
- [13]. Jalili M, Fathi M, Moradi-Lakeh M, Zehabchi S. Sublingual buprenorphine in acute pain management: a double-blind randomized clinical trial. *Ann Emerg Med.* 2011; 59(4):276–280. [PubMed: 22115823]
- [14]. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. *Arch Gen Psychiatry.* 1978; 35(4):501–516. [PubMed: 215096]
- [15]. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *N Engl J Med.* 2000; 343(18):1290–1297. [PubMed: 11058673]
- [16]. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. *J Pain Symptom Manage.* 2005; 29(3):297–326. [PubMed: 15781180]
- [17]. Jones JD, Sullivan MA, Manubay J, Vosburg SK, Comer SD. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, nonmalignant pain who are maintained on sublingual buprenorphine/naloxone. *Neuropsychopharmacology.* 2011; 36(2):411–422. [PubMed: 20980992]
- [18]. Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. *Can Fam Physician.* 2011a; 57(3):281–289. [PubMed: 21402963]
- [19]. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. *Can Fam Physician.* 2011b; 57(11):1269–1276. e1419–1228. [PubMed: 22084456]
- [20]. Keller CE, Ashrafioun L, Neumann AM, Van Klein J, Fox CH, Blondell RD. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. *Subst Abus.* 2012; 33(2):103–113. [PubMed: 22489582]
- [21]. Khosla N, Juon HS, Kirk GD, Astemborski J, Mehta SH. Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. *Addict Behav.* 2011; 36(12):1282–1287. [PubMed: 21868170]
- [22]. Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. *Eur J Pain.* 2005; 9(5):599–611. [PubMed: 16139189]
- [23]. Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. *Drug Alcohol Rev.* 2011; 30(3):300–305. [PubMed: 21545561]
- [24]. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry.* 1996; 53(5):401–407. [PubMed: 8624183]
- [25]. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. *Pain Physician.* 2010; 13(5):401–435. [PubMed: 20859312]
- [26]. Melzack R. The short-form McGill Pain Questionnaire. *Pain.* 1987; 30(2):191–197. [PubMed: 3670870]
- [27]. Naliboff BD, Wu SM, Schieffer B, Bolus R, Pham Q, Baria A, Aragaki D, Van Vort W, Davis F, Shekelle P. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. *J Pain.* 2011; 12(2):288–296. [PubMed: 21111684]

- [28]. Pade PA, Cardon KE, Hoffman RM, Geppert CM. Prescription opioid abuse, chronic pain, and primary care: A Co-Occurring Disorders Clinic in the chronic disease model. *J Subst Abuse Treat.* 2012
- [29]. Pergolizzi JV Jr, Gharibo C, Passik S, Labhsetwar S, Taylor R Jr, Pergolizzi JS, Muller-Schwefe G. Dynamic risk factors in the misuse of opioid analgesics. *J Psychosom Res.* 2012; 72(6):443–451. [PubMed: 22656441]
- [30]. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. *J Pain Symptom Manage.* 1993; 8(2):63–67. [PubMed: 8492004]
- [31]. Ripa SR, McCarberg BH, Munera C, Wen W, Landau CJ. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 mug/h or 20 mug/h in patients with osteoarthritis pain. *Expert Opin Pharmacother.* 2012; 13(9):1229–1241. [PubMed: 22409388]
- [32]. Roux P, Carrieri PM, Cohen J, Ravaux I, Spire B, Gossop M, Comer SD. Nonmedical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach. *Harm Reduct J.* 2011; 8:31. [PubMed: 22123176]
- [33]. Silversides A. Use of strong opioids in Canada rose sharply between 2005 and 2010. *BMJ.* 2011; 343:d5441. [PubMed: 21868459]
- [34]. Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. *J Pain Symptom Manage.* 2011; 42(6):903–917. [PubMed: 21945130]
- [35]. Townsend CO, Kerkvliet JL, Bruce BK, Rome JD, Hooten WM, Luedtke CA, Hodgson JE. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. *Pain.* 2008; 140(1):177–189. [PubMed: 18804915]
- [36]. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, Brownstein JS, Comer SD, Dart R, Dasgupta N, Denisco RA, Klein M, Leiderman DB, Lubran R, Rappaport BA, Zacny JP, Ahdieh H, Burke LB, Cowan P, Jacobs P, Malamut R, Markman J, Michna E, Palmer P, Peirce-Sandner S, Potter JS, Raja SN, Rauschkolb C, Roland CL, Webster LR, Weiss RD, Wolf K. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. *Pain.* 2012; 153(10):1997–2008. [PubMed: 22770841]
- [37]. Vowles KE, Ashworth J. Is opioid withdrawal necessary within comprehensive pain rehabilitation programs? *Pain.* 2011; 152(9):1948–1950. [PubMed: 21459513]
- [38]. Wesson DR, Smith DE. Buprenorphine in the treatment of opiate dependence. *J Psychoactive Drugs.* 2010; 42(2):161–175. [PubMed: 20648912]
- [39]. Wolfert MZ, Gilson AM, Dahl JL, Cleary JF. Opioid analgesics for pain control: wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practices. *Pain Med.* 2010; 11(3):425–434. [PubMed: 20002590]
- [40]. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics.* 1986; 42(1):121–130. [PubMed: 3719049]

Figure 1.
Time points of a laboratory session day during the second week of maintenance

Fig. 2.

Percentage of the sampled oxycodone dose chosen under each Bup/Nx maintenance dose.

Mann-Whitney tests: placebo vs 10 mg Oxy: Bup/Nx 2/0.5 mg, $P = .54$; Bup/Nx 8/2 mg, $P = .71$; Bup/Nx 16/4 mg, $P = .29$; placebo vs 20 mg Oxy: Bup/Nx 2/0.5 mg, $P = .29$; Bup/Nx 8/2 mg, $P = .74$; Bup/Nx 16/4 mg, $P = .14$; placebo vs 40 mg Oxy: Bup/Nx 2/0.5 mg, $P = .59$; Bup/Nx 8/2 mg, $P = .97$; Bup/Nx 16/4 mg, $P = .47$; placebo vs 60 mg Oxy: Bup/Nx 2/0.5 mg, $P = .18$; Bup/Nx 8/2 mg, $P = .36$; Bup/Nx 16/4 mg, $P = .37$. Oxy, oxycodone; Bup, buprenorphine; Nx, naloxone.

Table 1

Factors associated with oxycodone self-administration in a sample of opioid-dependent pain participants under buprenorphine maintenance during laboratory drug choice sessions. Logistic regression model based on Generalized Estimating Equations: bivariate analysis (n=25 participants, 375 observations)

Bivariate analysis				
	Number of sessions (%) or median [IQR]	Number of participants	OR (95%CI)	p- value
Age (years)	48 [43-54]		1.02 (0.91-1.15)	0.71
Gender				
Female	135 (36)	9	1	
Male	240 (64)	16	1.84 (0.26-13.08)	0.54
Years of education ^a	13 [12-14]		0.81 (0.55-1.19)	0.29
Ethnicity				
African American	135 (36)	9	1	
Caucasian	120 (32)	8	4.76 (0.83-27.2)	0.08
Hispanic	120 (32)	8	0.36 (0.02-6.72)	0.49
Percentage of participants employed	75 (20)	5	0.28 (0.01-6.46)	0.42
PO pills/day^{b,c}	7 [4-10]		1.09 (1.00-1.19)	0.04
Morphine equivalents mg/day ^b	60 [38-144]		1.23 (0.97-1.55)	0.08
Duration of PO use (years)	5 [2-8]		1.03 (0.86-1.23)	0.76
Benzodiazepine positive urine	60 (16)	4	4.76 (0.63-35.9)	0.13
Methadone positive urine ^{\$}	30 (8)	2	-	0.77
Cannabis positive urine ^{b \$}	30 (10)	2	-	0.14
Cocaine positive urine ^b	69 (14)	9	0.74 (0.04-14.78)	0.84
Self-reported heroin use ^{b \$}	15 (4)	1	-	0.08
Self-reported cocaine use ^b	45 (12)	3	1.57 (0.22-11.14)	0.65
Self-reported alcohol use^{b,d}	0 [0-4]		0.83 (0.57-1.20)	0.31
Buprenorphine/naloxone dose				
2/0.5 mg (ref)	125 (33)	25	1	
8/2 mg	125 (33)	25	0.79 (0.47-1.30)	0.35
16/4 mg	125 (33)	25	0.38 (0.19-0.77)	0.007
Oxycodone dose (PO)				
0 mg (ref)	75 (20)	25	1	

Bivariate analysis				
	Number of sessions (%) or median [IQR]	Number of participants	OR (95%CI)	p- value
10 mg	75 (20)	25	1.32 (0.63-2.81)	0.46
20 mg	75 (20)	25	1.36 (0.64-2.89)	0.42
40 mg	75 (20)	25	1.00 (0.46-2.19)	1.00
60 mg	75 (20)	25	1.54 (0.73-3.23)	0.26
MPQ score^{e,f}	21 [15-31]		1.30 (1.09-1.55)	0.003
SOWS score^{e,f}	4 [1-9]		1.89 (1.24-2.86)	0.003

* SA = self-administration of more than 60% of the total dose of oxycodone (drug break point > 1200)

^a for each grade year increase

^b at the consent visit before entering the study (baseline visit)

^c for 100 point-increase

^d number of drinks per month

^e 1 hour after the first daily dose of buprenorphine/naloxone

^f for each 10-unit increase

[§] not included in the final model; number of subjects < 10%

Tables 2a

Factors associated with oxycodone self-administration; Multivariate Logistic regression model based on Generalized Estimating Equations: multivariate analysis (n=25 subjects, 369 observations*)
Model 1 using withdrawal symptoms (SOWS score).

Multivariate analysis		
	aOR (95%CI)	p-value
Buprenorphine/naloxone dose		
2/0.5 mg (ref)	1	
8/2 mg	0.84 [0.50-1.42]	0.52
16/4 mg	0.41 [0.20-0.82]	0.01
SOWS score^{a,b}	1.96 [1.29-3.00]	0.002

^a 1 hour after the first daily dose of buprenorphine/naloxone

^b for each 10-unit increase

Table 2b

Model 2 using pain score (MPQ score).

Multivariate analysis		
Buprenorphine/naloxone dose		
2/0.5 mg (ref)	1	
8/2 mg	0.75 [0.42-1.33]	0.47
16/4 mg	0.42 [0.20-0.90]	0.03
MPQ score^{a,b}	1.59 [1.15-2.20]	0.005

^a 1 hour after the first daily dose of buprenorphine/naloxone^b for each 10-unit increase

*only the sessions with complete data in all the variables were included in the final model